CA2965211C - Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________ - Google Patents

Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________ Download PDF

Info

Publication number
CA2965211C
CA2965211C CA2965211A CA2965211A CA2965211C CA 2965211 C CA2965211 C CA 2965211C CA 2965211 A CA2965211 A CA 2965211A CA 2965211 A CA2965211 A CA 2965211A CA 2965211 C CA2965211 C CA 2965211C
Authority
CA
Canada
Prior art keywords
col
lung
collagen
type
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2965211A
Other languages
English (en)
French (fr)
Other versions
CA2965211A1 (en
Inventor
David S. Wilkes
Michael J. Klemsz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA2965211A1 publication Critical patent/CA2965211A1/en
Application granted granted Critical
Publication of CA2965211C publication Critical patent/CA2965211C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2965211A 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________ Active CA2965211C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75919506P 2006-01-13 2006-01-13
US60/759,195 2006-01-13
CA2641318A CA2641318C (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2641318A Division CA2641318C (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung

Publications (2)

Publication Number Publication Date
CA2965211A1 CA2965211A1 (en) 2007-10-25
CA2965211C true CA2965211C (en) 2020-06-30

Family

ID=38609836

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2965211A Active CA2965211C (en) 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________
CA2641318A Active CA2641318C (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2641318A Active CA2641318C (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung

Country Status (8)

Country Link
US (3) US7759075B2 (cg-RX-API-DMAC7.html)
EP (2) EP1977234B1 (cg-RX-API-DMAC7.html)
JP (2) JP5030973B2 (cg-RX-API-DMAC7.html)
CN (1) CN101375157B (cg-RX-API-DMAC7.html)
AU (1) AU2007238533C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706575B8 (cg-RX-API-DMAC7.html)
CA (2) CA2965211C (cg-RX-API-DMAC7.html)
WO (1) WO2007120947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238533C1 (en) * 2006-01-13 2013-08-15 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
EP2120967B1 (en) * 2006-11-28 2015-10-21 University Of Southern California Method for promoting wound healing
EP2395996A1 (en) * 2009-02-13 2011-12-21 Indiana University Research and Technology Corporation Compounds and methods for inhibiting mmp2 and mmp9
CN107243076A (zh) * 2009-04-22 2017-10-13 印第安那大学科技研究公司 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US8481333B2 (en) * 2011-05-31 2013-07-09 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
WO2013148232A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
JP6058354B2 (ja) * 2012-11-02 2017-01-11 東芝メディカルシステムズ株式会社 画像処理装置及び画像処理方法
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA2055813A1 (en) 1990-11-20 1992-05-21 Dariush Davalian Cyclosporin immunoassay
US6911220B1 (en) 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
JP2702354B2 (ja) * 1992-05-11 1998-01-21 帝人株式会社 血中の肺組織障害マーカー
US5778875A (en) * 1996-05-06 1998-07-14 U.S. Divers Co., Inc. First stage regulator and rotatable in-line valve
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US5962025A (en) 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
US5990274A (en) 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
WO2001057089A1 (en) * 2000-01-31 2001-08-09 Asahi Kasei Kabushiki Kaisha Antibody for detecting chlamydia pneumoniae
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US7348005B2 (en) 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
HUP0300997A2 (hu) * 2000-03-23 2003-07-28 Akzo Nobel N.V. A MIA-fehérje alkalmazása immunterápiában
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
WO2005101018A1 (en) * 2004-04-08 2005-10-27 Janssen Pharmaceutica N.V. Immunohistochemical detection method of collagen in a tissue sample
WO2007059211A2 (en) 2005-11-16 2007-05-24 The University Of Tennessee Research Foundation Methods of treating fibrosing diseases by induction of immune tolerance
AU2007238533C1 (en) * 2006-01-13 2013-08-15 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Also Published As

Publication number Publication date
AU2007238533C1 (en) 2013-08-15
EP2672266A3 (en) 2014-02-05
BRPI0706575B8 (pt) 2021-05-25
CN101375157B (zh) 2015-06-17
US20110183356A1 (en) 2011-07-28
US20090017013A1 (en) 2009-01-15
CN101375157A (zh) 2009-02-25
JP5936349B2 (ja) 2016-06-22
US7939281B2 (en) 2011-05-10
BRPI0706575A2 (pt) 2011-04-05
EP1977234B1 (en) 2015-11-04
CA2641318A1 (en) 2007-10-25
EP1977234A1 (en) 2008-10-08
JP2009524023A (ja) 2009-06-25
US20110020838A1 (en) 2011-01-27
US7759075B2 (en) 2010-07-20
JP5030973B2 (ja) 2012-09-19
AU2007238533B2 (en) 2012-09-20
AU2007238533A1 (en) 2007-10-25
EP2672266B1 (en) 2018-08-01
WO2007120947A1 (en) 2007-10-25
EP1977234A4 (en) 2009-06-03
JP2012108137A (ja) 2012-06-07
CA2965211A1 (en) 2007-10-25
EP2672266A2 (en) 2013-12-11
CA2641318C (en) 2017-06-20
BRPI0706575B1 (pt) 2018-12-11
US8039225B2 (en) 2011-10-18
HK1126861A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
US8039225B2 (en) Method to identify patients at risk for lung transplant rejection
Yasufuku et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection
US20170240634A1 (en) Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
Hodson et al. Steroid sensitive nephrotic syndrome
RU2723554C2 (ru) Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови
US9005982B2 (en) Biomarkers associated with autoimmune diseases of the lung
CN102458446B (zh) 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
US11090310B2 (en) Methods and compositions for treating hypertriglyceridemia
HK1126861B (en) Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
US7348005B2 (en) Oral tolerance induction by collagen to prevent allograft rejection
US20040002113A1 (en) Detection and treatment methods for type I diabetes
Aziz et al. Immunobiology, diagnosis, and treatment of rejection
WO2019077143A1 (en) METHODS AND COMPOSITIONS FOR PREDICTING AND PRECOCUALLY DIAGNOSING A CHRONIC ACTIVE FORM OF ABMR WITH GRAFT GLOMERULOPATHY AND RENAL TRANSPLANT LOSS
WO2009104388A1 (ja) 膠原病の予防・治療剤
Ratkay Investigation of an adjuvant-enhanced model of murine arthritis and its therapeutic application
CA2402489C (en) Oral tolerance induction by collagen to prevent allograft rejection
Backman et al. Chronic cutaneous bacterial hypersensitivity
Abuzakouk et al. Irish society for rheumatology Proceedings of Annual General Meeting held 14th October, 1994 at St. James’s Hospital, Dublin 8

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103